Markus Borner
Markus Borner
Unknown affiliation
Verified email at muri-be.ch
Title
Cited by
Cited by
Year
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan, ME Scheulen, S Johnston, K Mross, F Cardoso, C Dittrich, ...
Journal of Clinical Oncology 23 (23), 5314-5322, 2005
5262005
The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression
S Vonlanthen, J Heighway, HJ Altermatt, M Gugger, A Kappeler, ...
British journal of cancer 84 (10), 1372-1376, 2001
3882001
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
MM Borner, P Schöffski, R De Wit, F Caponigro, G Comella, A Sulkes, ...
European Journal of Cancer 38 (3), 349-358, 2002
3602002
Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
W Scheithauer, J McKendrick, S Begbie, M Borner, WI Burns, HA Burris, ...
Annals of Oncology 14 (12), 1735-1743, 2003
3272003
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized …
AD Roth, N Fazio, R Stupp, S Falk, J Bernhard, P Saletti, D Köberle, ...
Journal of Clinical Oncology 25 (22), 3217-3223, 2007
3112007
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
AD Roth, R Maibach, G Martinelli, N Fazio, MS Aapro, O Pagani, R Morant, ...
Annals of oncology 11 (3), 301-306, 2000
3052000
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
J Carmichael, T Popiela, D Radstone, S Falk, M Borner, A Oza, ...
Journal of clinical oncology 20 (17), 3617-3627, 2002
3002002
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with …
JR Hecht, T Trarbach, E Jaeger, J Hainsworth, R Wolff, K Lloyd, G Bodoky, ...
Journal of Clinical Oncology 23 (16_suppl), LBA3-LBA3, 2005
2502005
Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer
MM Borner, D Dietrich, R Stupp, R Morant, H Honegger, M Wernli, ...
Journal of clinical oncology 20 (7), 1759-1766, 2002
2092002
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after …
M Borner, M Bacchi, A Goldhirsch, R Greiner, F Harder, M Castiglione, ...
Journal of clinical oncology 12 (10), 2071-2077, 1994
2071994
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
D Crivellari, O Pagani, A Veronesi, D Lombardi, F Nole, B Thürlimann, ...
Annals of oncology 12 (3), 353-356, 2001
1602001
Mitomycin C induces apoptosis and caspase-8 and-9 processing through a caspase-3 and Fas-independent pathway
F Pirnia, E Schneider, DC Betticher, MM Borner
Cell Death & Differentiation 9 (9), 905-914, 2002
1542002
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors
D BOHLEN, M BORNER, RW SONNTAG, MF FEY, URSE STUDER
The Journal of urology 161 (4), 1148-1152, 1999
1471999
Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis
M Scholz, M Zehender, GN Thalmann, M Borner, H Thöni, UE Studer
Annals of oncology 13 (1), 121-124, 2002
1462002
Answering patients' needs: oral alternatives to intravenous therapy
M Borner, W Scheithauer, C Twelves, J Maroun, H Wilke
The oncologist 6, 12-16, 2001
1442001
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical …
M Borner, D Koeberle, R Von Moos, P Saletti, D Rauch, V Hess, A Trojan, ...
Annals of oncology 19 (7), 1288-1292, 2008
1362008
Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
S Vonlanthen, J Heighway, MP Tschan, MM Borner, HJ Altermatt, ...
Oncogene 17 (21), 2779-2785, 1998
1341998
Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3
MM Borner, CE Myers, O Sartor, Y Sei, T Toko, JB Trepel, E Schneider
Cancer research 55 (10), 2122-2128, 1995
1341995
PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
S Frese, F Pirnia, D Miescher, S Krajewski, MM Borner, JC Reed, ...
Oncogene 22 (35), 5427-5435, 2003
1292003
Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemia
Y Sei, DKJE Von Lubitz, AS Basile, MM Borner, RCS Lin, P Skolnick, ...
Neuroscience letters 171 (1-2), 179-182, 1994
1271994
The system can't perform the operation now. Try again later.
Articles 1–20